The ESMO Deep Dive - Upper Digestive Cancers Webinar Series recordings and slides are available to all ESMO Members.
ESMO Deep Dive: Upper Digestive Cancers - Pancreatic Cancer: From Molecule To Medicine
It is with great pleasure that we invite you to participate in the ESMO Deep Dive Webinar on pancreatic cancer, elaborating the facts from molecule to medicine.
This webinar is developed with the aim to understand different types of models for studying pancreatic cancer along their limitations, to review KRAS targeting and the current pre-clinical and early clinical approaches, discuss homologous repair deficiency, immunotherapy and other novel pathways targeting in pancreatic cancer, and to understand how the genomic and biologic underpinnings of pancreatic cancer are being translated into clinical practice.
We are delighted to announce the distinguished speakers who will join us in this webinar. We will begin with a lecture on best pre-clinical models for pancreatic cancer. This will follow with elaboration of novel KRAS directed therapies for pancreatic cancer. Finally, we will review molecular biology of pancreatic cancer from the aspect of treatment individualisation. The lectures will be followed by a live discussion with the full speakers’ panel.
The programme is designed to provide an overview of the latest understanding of molecular biology and the impact of targeting different pathways in the management of patients with pancreatic cancer, offer expert opinion exchange and provide some important considerations in this field. We strongly encourage and invite you to register and join us all in this new ESMO activity.
Prof. Eileen M. O’Reilly
Memorial Sloan Kettering Cancer Center, New York, United States
Weill Cornell Medical College, Cornell University, New York, United States
AND
Prof. Stefano Cascinu
San Raffaele Hospital, Milan Italy
Speakers
Programme
Time |
Title |
Speaker |
---|---|---|
5 min |
Welcome and Introduction |
Eileen O’Reilly, Stefano Cascinu |
25 min |
What are the best pre-clinical models for pancreatic cancer? |
Kenneth Olive |
25 min |
Novel KRAS directed therapies in pancreatic cancer |
Andrew Aguirre |
25 min |
Molecular tumour biology and treatment individualisation: hope or hype? |
Thomas Seufferlein |
15 min |
LIVE Q&A |
All |
A certificate of attendance and 2 ESMO-MORA category 1 points will be awarded for live attendance at this event
Learning objectives:
- To understand different types of models for pancreatic cancer along limitations
- To review KRAS targeting and the pre-clinical and early clinical approaches currently in development for pancreatic cancer
- To discuss homologous repair deficiency, immune therapy and other novel pathways targeting in pancreatic cancer
- To understand how the genomic and biologic underpinnings of pancreatic cancer are being translated into practice